AMBER ESQUIVEL: Open Payments
NPI 1053142240 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,013 in 52 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $405 · 2025 $1,013
Food & beverage: $1,013
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 21 | $412 |
| AstraZeneca Pharmaceuticals LP | 7 | $146 |
| Lilly USA, LLC | 6 | $106 |
| ABBVIE INC. | 3 | $68 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $65 |
| PFIZER INC. | 3 | $55 |
| ALK-Abello, Inc | 2 | $52 |
| Merck Sharp & Dohme LLC | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
Products named: Wegovy, FARXIGA, Rybelsus, MOUNJARO, Ozempic, Kerendia, Grastek, UBRELVY.
Industry payments across TX — which companies pay providers there.
